Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism

被引:530
作者
Williams, DR
de Silva, R
Paviour, DC
Pittman, A
Watt, HC
Kilford, L
Holton, JL
Revesz, T
Lees, AJ
机构
[1] UCL, Reta Lila Weston Inst Neurol Studies, London W1T 4JF, England
[2] UCL, Queen Sq Brain Bank Neurol Disorders, London W1T 4JF, England
[3] UCL, Inst Neurol, London W1T 4JF, England
[4] London Sch Hyg & Trop Med, Sara Koe PSP Res Ctr, London WC1, England
[5] London Sch Hyg & Trop Med, Med Stat Unit, London WC1, England
关键词
progressive supranuclear palsy; PSP; Richardson's syndrome; PSP-P; tau;
D O I
10.1093/brain/awh488
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The clinical diagnosis of progressive supranuclear palsy (PSP) relies on the identification of characteristic signs and symptoms. A proportion of pathologically diagnosed cases do not develop these classic features, prove difficult to diagnose during life and are considered as atypical PSP. The aim of this study was to examine the apparent clinical dichotomy between typical and atypical PSP, and to compare the biochemical and genetic characteristics of these groups. In 103 consecutive cases of pathologically confirmed PSP, we have identified two clinical phenotypes by factor analysis which we have named Richardson's syndrome (RS) and PSP-parkinsonism (PSP-P). Cases of RS syndrome made up 54% of all cases, and were characterized by the early onset of postural instability and falls, supranuclear vertical gaze palsy and cognitive dysfunction. A second group of 33 (32%) were characterized by asymmetric onset, tremor, a moderate initial therapeutic response to levodopa and were frequently confused with Parkinson's disease (PSP-P). Fourteen cases (14%) could not be separated according to these criteria. In RS, two-thirds of cases were men, whereas the sex distribution in PSP-P was even. Disease duration in RS was significantly shorter (5.9 versus 9.1 years, P < 0.001) and age at death earlier (72.1 versus 75.5 years, P = 0.01) than in PSP-P. The isoform composition of insoluble tangle-tau isolated from the basal pons also differed significantly. In RS, the mean four-repeat:three-repeat tau ratio was 2.84 and in PSP-P it was 1.63 (P < 0.003). The effect of the H1,H1 PSP susceptibility genotype appeared stronger in RS than in PSP-P (odds ratio 13.2 versus 4.5). The difference in genotype frequencies between the clinical subgroups was not significant. There were no differences in apolipoprotein E genotypes. The classic clinical description of PSP, which includes supranuclear gaze palsy, early falls and dementia, does not adequately describe one-third of cases in this series of pathologically confirmed cases. We propose that PSP-P represents a second discrete clinical phenotype that needs to be clinically distinguished from classical PSP (RS). The different tau isoform deposition in the basal pons suggests that this may ultimately prove to be a discrete nosological entity.
引用
收藏
页码:1247 / 1258
页数:12
相关论文
共 70 条
[31]   CONSTANT NEUROFIBRILLARY CHANGES IN THE NEOCORTEX IN PROGRESSIVE SUPRANUCLEAR PALSY - BASIC DIFFERENCES WITH ALZHEIMERS-DISEASE AND AGING [J].
HAUW, JJ ;
VERNY, M ;
DELAERE, P ;
CERVERA, P ;
HE, Y ;
DUYCKAERTS, C .
NEUROSCIENCE LETTERS, 1990, 119 (02) :182-186
[32]   The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service [J].
Hughes, AJ ;
Daniel, SE ;
Ben-Shlomo, Y ;
Lees, AJ .
BRAIN, 2002, 125 :861-870
[33]   Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease [J].
Hughes, AJ ;
Daniel, SE ;
Lees, AJ .
NEUROLOGY, 2001, 57 (08) :1497-1499
[34]   Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17 [J].
Hutton, M ;
Lendon, CL ;
Rizzu, P ;
Baker, M ;
Froelich, S ;
Houlden, H ;
Pickering-Brown, S ;
Chakraverty, S ;
Isaacs, A ;
Grover, A ;
Hackett, J ;
Adamson, J ;
Lincoln, S ;
Dickson, D ;
Davies, P ;
Petersen, RC ;
Stevens, M ;
de Graaff, E ;
Wauters, E ;
van Baren, J ;
Hillebrand, M ;
Joosse, M ;
Kwon, JM ;
Nowotny, P ;
Che, LK ;
Norton, J ;
Morris, JC ;
Reed, LA ;
Trojanowski, J ;
Basun, H ;
Lannfelt, L ;
Neystat, M ;
Fahn, S ;
Dark, F ;
Tannenberg, T ;
Dodd, PR ;
Hayward, N ;
Kwok, JBJ ;
Schofield, PR ;
Andreadis, A ;
Snowden, J ;
Craufurd, D ;
Neary, D ;
Owen, F ;
Oostra, BA ;
Hardy, J ;
Goate, A ;
van Swieten, J ;
Mann, D ;
Lynch, T .
NATURE, 1998, 393 (6686) :702-705
[35]   PROGRESSIVE SUPRANUCLEAR PALSY (SUBCORTICAL ARGYROPHILIC DYSTROPHY [J].
JELLINGER, K .
ACTA NEUROPATHOLOGICA, 1971, 19 (04) :347-+
[36]   MESENCEPHALIC CHOLINERGIC NUCLEI IN PROGRESSIVE SUPRANUCLEAR PALSY [J].
JUNCOS, JL ;
HIRSCH, EC ;
MALESSA, S ;
DUYCKAERTS, C ;
HERSH, LB ;
AGID, Y .
NEUROLOGY, 1991, 41 (01) :25-30
[37]  
KSIEZAKREDING H, 1994, AM J PATHOL, V145, P1496
[38]  
LANDWEHRMEYER B, 1994, J NEURAL TRANSM-SUPP, P229
[39]   Cognitive, neuroimaging, and pathological studies in a patient with Pick's disease [J].
Lieberman, AP ;
Trojanowski, JQ ;
Lee, VMY ;
Balin, BJ ;
Ding, XS ;
Greenberg, J ;
Morrison, D ;
Reivich, M ;
Grossman, M .
ANNALS OF NEUROLOGY, 1998, 43 (02) :259-265
[40]  
Litvan I, 1999, J NEUROL, V246, P1